 | • レポートコード：TPM-NV210 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、148ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、精神分裂病治療薬の世界市場について調べ、精神分裂病治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（第一世代薬物、第二世代薬物、および第三世代薬物）分析、投与経路別（経口および注射）分析、関連企業情報などをまとめました。 ・精神分裂病治療薬の市場概要 ・精神分裂病治療薬の市場動向 ・精神分裂病治療薬の世界市場規模・予測 ・精神分裂病治療薬市場：薬物クラス別（第一世代薬物、第二世代薬物、および第三世代薬物） ・精神分裂病治療薬市場：投与経路別（経口および注射） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.
Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.
Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Schizophrenia Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Schizophrenia Drugs Introduction
4.1.2. Market Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027
4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast
5. Key Insights
5.1. Pipeline Analysis: Schizophrenia Drugs
5.2. Value Chain Analysis
5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027
6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definitions
6.2. Key Findings / Developments
6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. First Generation Drugs
6.3.2. Second Generation Drugs
6.3.3. Third Generation Drugs
6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class
7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definitions
7.2. Key Findings / Developments
7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
7.3.1. Injectable
7.3.2. Oral
7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration
8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Schizophrenia Drugs Market Attractiveness, by Region
9. North America Schizophrenia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. First Generation Drugs
9.2.2. Second Generation Drugs
9.2.3. Third Generation Drugs
9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
9.3.1. Injectable
9.3.2. Oral
9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Schizophrenia Drugs Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Route of Administration
9.5.3. By Country
10. Europe Schizophrenia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. First Generation Drugs
10.2.2. Second Generation Drugs
10.2.3. Third Generation Drugs
10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
10.3.1. Injectable
10.3.2. Oral
10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Route of Administration
10.5.3. By Country/Sub-region
11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. First Generation Drugs
11.2.2. Second Generation Drugs
11.2.3. Third Generation Drugs
11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.3.1. Injectable
11.3.2. Oral
11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Route of Administration
11.5.3. By Country/Sub-region
12. Latin America Schizophrenia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. First Generation Drugs
12.2.2. Second Generation Drugs
12.2.3. Third Generation Drugs
12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.3.1. Injectable
12.3.2. Oral
12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Country/Sub-region
13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. First Generation Drugs
13.2.2. Second Generation Drugs
13.2.3. Third Generation Drugs
13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.3.1. Injectable
13.3.2. Oral
13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Route of Administration
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)
14.2. Company Profiles
14.2.1. Allergan
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Otsuka Holdings Co., Ltd
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Janssen Pharmaceutica (Johnson & Johnson)
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Pfizer Inc.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Maynepharma
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Vanda Pharmaceuticals Inc.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Sumitomo Dainippon Pharma
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview
14.2.8. Eli Lilly & Co.
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Financial Overview
14.2.8.3. Product Portfolio
14.2.8.4. SWOT Analysis
14.2.8.5. Strategic Overview
14.2.9. AstraZeneca Plc
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Financial Overview
14.2.9.3. Product Portfolio
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview